Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2024-08-27 Regulatory Filings
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
公告本公司婦產科用產品”PROTAHERE”可吸收防沾黏凝膠 6ml及10ml取得銷售許可證書
Regulatory Filings Classification · 95% confidence The document is a short announcement (826 characters) from a listed company about obtaining a sales permit for a medical product. It does not contain financial data, management discussion, or detailed report content. It is a regulatory announcement about a product approval, which affects company operations but is not a financial report or meeting material. The document fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-08-27 Chinese
113年8月變更登記
Share Issue/Capital Change Classification · 95% confidence The document contains detailed information about the company's share capital, including authorized capital, paid-in capital, and sources of capital changes such as cash capital increase, capital reserve conversion, earnings conversion, and convertible bonds converted to common stock. It does not contain financial statements, management discussion, or audit information. The document is relatively short (814 characters) and appears to be a regulatory disclosure about capital structure and changes. This fits the description of a Share Issue/Capital Change announcement rather than a full financial report or other categories.
2024-08-16 Chinese
公告本公司一針劑型透明質酸”JETKNEE”及三針劑型 ”FLEXVISC”關節腔注射劑產品取得銷售許可證書
Regulatory Filings Classification · 95% confidence The document is a short announcement (835 characters) from a company named 科妍生物科技股份有限公司 about obtaining sales permits for certain medical products. It includes details such as the event date, company name, product information, and regulatory compliance references. There are no financial statements, no detailed financial analysis, no management discussion, or any form of report attached or referenced. The content is a regulatory announcement about a product approval, which does not fit into financial reports or management reports categories. It is not a report publication announcement since it does not mention any report being published or attached. Given the nature and length, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-08-12 Chinese
公告本公司刺激自體膠原蛋白增生長效型聚己內酯(PCL)皮下 填補劑產品喬凡霓絲皮下植入劑取得中華民國衛生福利部(TFDA) 核發第三類醫材銷售許可證。
Regulatory Filings Classification · 95% confidence The document is a short announcement (882 characters) from a listed company (科妍) reporting the approval of a medical product by the Taiwan Food and Drug Administration (TFDA). It is a factual disclosure about a regulatory approval event, not a financial report or detailed management discussion. There is no financial data, no mention of annual or quarterly results, no voting results, no board changes, no merger activity, or other report types. The document is a regulatory announcement about a material event affecting the company, fitting the category of Regulatory Filings (RNS).
2024-08-12 Chinese
公告本公司國內第二次無擔保轉換公司債113年第2季轉換 普通股之發行新股基準日
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from a listed company (1786 科妍) regarding the issuance of new shares due to the conversion of domestic unsecured convertible bonds in the second quarter of the year 113 (Taiwan calendar, corresponding to 2024). It details the board resolution date, the amount and number of shares issued, share capital before and after the increase, and other issuance specifics. The content focuses on capital changes related to share issuance rather than financial results, management changes, or meeting materials. The document length is short (958 characters) and is a regulatory announcement about share issuance. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2024-08-08 Chinese
公告本公司董事會通過113年第2季合併財務報告
Interim / Quarterly Report Classification · 95% confidence The document is a public announcement from a listed company (1786 科妍) reporting the board's approval of the consolidated financial report for the second quarter of the year 113 (Taiwan calendar, equivalent to 2024). It includes cumulative financial figures for the period 113/01/01 to 113/06/30, such as revenue, gross profit, operating profit, net profit, EPS, total assets, liabilities, and equity. The document is short (901 characters) and primarily serves as a formal announcement of the board's approval of the interim financial report rather than the full report itself. It contains substantive financial data for a period shorter than a full fiscal year (half-year). Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-08 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.